A61K 31/542
Ortho- or peri-condensed with heterocyclic ring systems
Official title: ortho- or peri-condensed with heterocyclic ring systems
A61K31/542 (Ortho- or peri-condensed with heterocyclic ring systems) appears on 1,055 US grants and 1,551 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,055
- Published applications
- 1,551
- Assignees
- 760
- Inventors
- 3,229
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 22 | 0 |
| 1977 | 16 | 0 |
| 1978 | 16 | 0 |
| 1979 | 15 | 0 |
| 1980 | 8 | 0 |
| 1981 | 18 | 0 |
| 1982 | 4 | 0 |
| 1983 | 10 | 0 |
| 1984 | 12 | 0 |
| 1985 | 9 | 0 |
| 1986 | 6 | 0 |
| 1987 | 10 | 0 |
| 1988 | 5 | 0 |
| 1989 | 8 | 0 |
| 1990 | 9 | 0 |
| 1991 | 1 | 0 |
| 1992 | 7 | 0 |
| 1993 | 4 | 0 |
| 1994 | 3 | 0 |
| 1995 | 6 | 0 |
| 1996 | 4 | 0 |
| 1997 | 13 | 0 |
| 1998 | 13 | 0 |
| 1999 | 14 | 0 |
| 2000 | 13 | 0 |
| 2001 | 7 | 1 |
| 2002 | 18 | 24 |
| 2003 | 11 | 37 |
| 2004 | 5 | 49 |
| 2005 | 7 | 28 |
| 2006 | 7 | 35 |
| 2007 | 6 | 46 |
| 2008 | 6 | 44 |
| 2009 | 11 | 30 |
| 2010 | 23 | 41 |
| 2011 | 10 | 32 |
| 2012 | 26 | 41 |
| 2013 | 25 | 65 |
| 2014 | 46 | 111 |
| 2015 | 73 | 105 |
| 2016 | 63 | 105 |
| 2017 | 73 | 101 |
| 2018 | 61 | 96 |
| 2019 | 62 | 74 |
| 2020 | 62 | 87 |
| 2021 | 36 | 86 |
| 2022 | 43 | 88 |
| 2023 | 38 | 69 |
| 2024 | 31 | 70 |
| 2025 | 39 | 47 |
| 2026 | 20 | 39 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- MRGX receptor antagonists6 Oct 2026US 12,751,953 B2Katholieke Universiteit Leuven of KU Leuven Research & Development
- Ionic liquids for transdermal drug delivery6 Oct 2026US 12,752,009 B2Arizona Board of Regents
- Combinatory treatment29 Sep 2026US 12,746,216 B2Arivin Therapeutics Oy
- Use of membrane inhibitors to enhance vaccine development against enveloped viruses8 Sep 2026US 12,728,161 B2Cornell University
- CXCL8 inhibitors for use in the treatment of COVID-1926 May 2026US 12,636,268 B2Dompé Farmaceutici S.P.A.
- Guanidinylated Amphiphilic Tobramycin Derivates and B-Lactam/B-Lactamase Inhibitor Combinations for Treatment of Pseudomonas Aeruginosa Infections8 Oct 2026US 2026/0306524 A1
- Tp0751 chimera-containing vaccine1 Oct 2026US 2026/0297141 A1University of Washington
- Ophthalmic Solution of Brinzolamide24 Sep 2026US 2026/0284070 A1Micro Labs Limited
- Heteroaryl derivatives as ddrs inhibitors24 Sep 2026US 2026/0285855 A1Chiesi Farmaceutici S.P. A.
- Boronic acid derivatives and therapeutic uses thereof17 Sep 2026US 2026/0272962 A1Qpex Biopharma, Inc.
Most cited
By later US patents
- Method for manufacturing a porous ceramic scaffold having an organic/inorganic hybrid coating layer containing a bioactive factor777US 8,734,831 B2Snu R&Db Foundation · 2014
- Pharmaceutical and cosmetic carrier or composition for topical application284US 6,911,211 B2Foamix Ltd. · 2005
- Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth243US 6,861,053 B1Cedars-Sinai Medical Center · 2005
- Probiotic recolonisation therapy240US 8,460,648 B22013
- Method for treatment of idiopathic inflammatory bowel disease (IIBD)229US 5,599,795 A1997